Tuesday, May 2, 2023 | The Latest Research, Commentary, And News From Health Affairs
Dear John,
We've announced several new events for May, including a Policy Spotlight with Dawn O’Connell, assistant secretary for preparedness and
response, US Department of Health and Human Services. Take a look at what else is upcoming this month.
Financial Incentives And Biosimilar
Uptake
Under the 340B Drug Pricing Program, eligible hospitals receive substantial discounts on drug purchases, creating opportunities for them to earn higher profits from higher-cost
discounted drugs than from lower-cost undiscounted drugs.
The 340B program is also associated with "more hospital-based administrations of and revenues from biologic medications overall."
"Our findings point to the 340B program as one driver of provider variation in uptake of biosimilars," the authors conclude. "Given the large proportion of hospitals participating in the 340B program, it could be a factor that has meaningfully reduced overall biosimilar use in the US."
Want to learn more about this research? Amelia Bond joined us on A Health Podyssey today to discuss the paper's findings in greater detail. Listen here.
Health Affairs Editor-in-Chief Alan Weil interviews Amelia Bond from Weill Cornell Medical College on her paper exploring whether participation in the 340B drug program influences biosimilar uptake.
Health Affairs is the leading peer-reviewedjournalat the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking
content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
